Gianpaolo Zerbini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gianpaolo Zerbini has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
Anna Maestroni
IRCCS San Raffaele Scientific Institute, Milan, Italy
12 shared publications- Rosangela Lattanzio
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy
5 shared publications Silvia Maestroni
IRCCS San Raffaele Scientific Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
5 shared publicationsDaniela Gabellini
IRCCS San Raffaele Scientific Institute, Milan, Italy
4 shared publicationsGemma Tremolada
Department of Ophthalmology Vita‐Salute University San Raffaele Scientific Institute Milan Italy
4 shared publicationsAlessio Palini
Flow Cytometry Resource Laboratory, San Raffaele Scientific Institute, Milan, Italy; and
3 shared publications
Latest Publications
- 1 December 2014
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 64 (6) , 1003-1005
Viable Podocyturia in Healthy Individuals: Implications for Podocytopathies
- 1 December 2014
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 64 (6) , 1003-1005
Viable Podocyturia in Healthy Individuals: Implications for Podocytopathies
- 1 October 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (3) , e218-22
Effect of chromogranin A‐derived vasostatin‐1 on laser‐induced choroidal neovascularization in the mouse
Purpose: To verify the effect of vasostatin‐1 (VS‐1), an anti‐angiogenic fragment of chromogranin A, in the prevention of choroidal neovascularization (CNV) in an established mouse model of laser‐induced ocular neovascularization.Methods: Bruch's membrane, the innermost layer of the choroid, was broken by laser photocoagulation in C57/Bl6 mice, to induce CNV. Mice were then treated daily for 14 days by intraperitoneal injection of VS‐1 or vehicle (6 mice/group). CNV and vascular leakage were measured at three time‐points (day 0, 7 and 14) in vivo by spectral domain optical coherence tomography (OCT) and fluorescein angiography (FA). Ex vivo analysis of CNV was also performed at day 14 by confocal microscopy analysis of dextran‐perfused choroidal flat‐mounts.Results: In vivo analyses showed that VS‐1 significantly reduced CNV at day 14 (p = 0.03) and vascular leakage at day 7 (p = 0.01) and 14 (p = 0.04). Ex vivo confocal microscopy analysis of CNV performed on dextran‐perfused choroidal flat‐mounts at day 14 confirmed the protective activity of VS‐1 (p = 0.01). A significant correlation between the results of in vivo and ex vivo analyses of CNV was also observed (p = 0.001, R2 = 0.81).Conclusion: The results indicate that VS‐1 can prevent CNV and vascular leakage in a mouse model of ocular neovascularization, suggesting that this polypeptide might have therapeutic activity in human ocular diseases that are complicated by neovascularization or excessive vascular permeability.
- 1 October 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (3) , e218-22
Effect of chromogranin A‐derived vasostatin‐1 on laser‐induced choroidal neovascularization in the mouse
Purpose: To verify the effect of vasostatin‐1 (VS‐1), an anti‐angiogenic fragment of chromogranin A, in the prevention of choroidal neovascularization (CNV) in an established mouse model of laser‐induced ocular neovascularization.Methods: Bruch's membrane, the innermost layer of the choroid, was broken by laser photocoagulation in C57/Bl6 mice, to induce CNV. Mice were then treated daily for 14 days by intraperitoneal injection of VS‐1 or vehicle (6 mice/group). CNV and vascular leakage were measured at three time‐points (day 0, 7 and 14) in vivo by spectral domain optical coherence tomography (OCT) and fluorescein angiography (FA). Ex vivo analysis of CNV was also performed at day 14 by confocal microscopy analysis of dextran‐perfused choroidal flat‐mounts.Results: In vivo analyses showed that VS‐1 significantly reduced CNV at day 14 (p = 0.03) and vascular leakage at day 7 (p = 0.01) and 14 (p = 0.04). Ex vivo confocal microscopy analysis of CNV performed on dextran‐perfused choroidal flat‐mounts at day 14 confirmed the protective activity of VS‐1 (p = 0.01). A significant correlation between the results of in vivo and ex vivo analyses of CNV was also observed (p = 0.001, R2 = 0.81).Conclusion: The results indicate that VS‐1 can prevent CNV and vascular leakage in a mouse model of ocular neovascularization, suggesting that this polypeptide might have therapeutic activity in human ocular diseases that are complicated by neovascularization or excessive vascular permeability.
- 1 September 2014
- Published by Wolters Kluwer Health in Retina
- Vol. 34 (9) , 1802-1810
ENDOTHELIAL PROGENITOR CELLS AND RESPONSE TO RANIBIZUMAB IN AGE-RELATED MACULAR DEGENERATION
Background: Choroidal neovascularization (CNV) is the main cause of vision loss in age-related macular degeneration (AMD). In experimental CNV, endothelial progenitor cells (EPCs) contribute to the formation of new vessels. The aim of this study was to investigate whether the behavior of EPCs in patients with AMD supports a role for EPCs in human CNV. Methods: The number of circulating EPCs that are considered pure endothelial precursors and EPCs with monocytic characteristics, and the plasma levels of regulatory cytokines were evaluated in 23 patients with AMD with active CNV and 20 matched controls. In the patients, this profile was re-evaluated after ranibizumab. Results: When compared with controls, the patients with AMD showed a lower number of both EPC types (P = 0.03) and higher plasma levels (P = 0.03) of stromal cell–derived factor 1. Three monthly injections of ranibizumab returned to control levels the number of circulating EPCs considered pure endothelial precursors and of stromal cell–derived factor 1, but not of monocytic EPCs. Conclusion: The observations indicate responsiveness of circulating EPCs to the CNV process in AMD. They suggest the hypothesis that increased stromal cell–derived factor 1 production at the CNV site (reflected in higher plasma levels) recruits EPCs from the circulation, and that antivascular endothelial growth factor therapy selectively decreases the recruitment of cells to be incorporated into new vessels.
- 1 September 2014
- Published by Wolters Kluwer Health in Retina
- Vol. 34 (9) , 1802-1810
ENDOTHELIAL PROGENITOR CELLS AND RESPONSE TO RANIBIZUMAB IN AGE-RELATED MACULAR DEGENERATION
Background: Choroidal neovascularization (CNV) is the main cause of vision loss in age-related macular degeneration (AMD). In experimental CNV, endothelial progenitor cells (EPCs) contribute to the formation of new vessels. The aim of this study was to investigate whether the behavior of EPCs in patients with AMD supports a role for EPCs in human CNV. Methods: The number of circulating EPCs that are considered pure endothelial precursors and EPCs with monocytic characteristics, and the plasma levels of regulatory cytokines were evaluated in 23 patients with AMD with active CNV and 20 matched controls. In the patients, this profile was re-evaluated after ranibizumab. Results: When compared with controls, the patients with AMD showed a lower number of both EPC types (P = 0.03) and higher plasma levels (P = 0.03) of stromal cell–derived factor 1. Three monthly injections of ranibizumab returned to control levels the number of circulating EPCs considered pure endothelial precursors and of stromal cell–derived factor 1, but not of monocytic EPCs. Conclusion: The observations indicate responsiveness of circulating EPCs to the CNV process in AMD. They suggest the hypothesis that increased stromal cell–derived factor 1 production at the CNV site (reflected in higher plasma levels) recruits EPCs from the circulation, and that antivascular endothelial growth factor therapy selectively decreases the recruitment of cells to be incorporated into new vessels.
- Open Access
- 1 January 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 59
Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study
The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF’s KDOQI) staging system for chronic kidney disease (CKD) is based primarily on estimated GFR (eGFR). This study aimed at assessing whether reclassification of subjects with type 2 diabetes using two recent classifications based on both eGFR and albuminuria, the Alberta Kidney Disease Network (AKDN) and the Kidney Disease: Improving Global Outcomes (KDIGO), provides a better definition of burden from cardiovascular disease (CVD) and diabetic retinopathy (DR) than the NKF’s KDOQI classification.
- 1 January 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 59
Open AccessDistribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study
The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF’s KDOQI) staging system for chronic kidney disease (CKD) is based primarily on estimated GFR (eGFR). This study aimed at assessing whether reclassification of subjects with type 2 diabetes using two recent classifications based on both eGFR and albuminuria, the Alberta Kidney Disease Network (AKDN) and the Kidney Disease: Improving Global Outcomes (KDIGO), provides a better definition of burden from cardiovascular disease (CVD) and diabetic retinopathy (DR) than the NKF’s KDOQI classification.
- Open Access
- 5 July 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 1-98
Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study
Background: Previous reports have clearly indicated a significant relationship between hemoglobin (Hb) A1c change from one visit to the next and microvascular complications, especially nephropathy (albuminuria and albuminuric chronic kidney disease, CKD). In contrast, data on macrovascular disease are less clear. This study was aimed at examining the association of HbA1c variability with cardiovascular disease (CVD) in the large cohort of subjects with type 2 diabetes from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Methods: Serial (3–5) HbA1c values obtained during the 2-year period preceding recruitment, including that obtained at the enrolment, were available from 8,290 subjects from 9 centers (out of 15,773 patients from 19 centers). Average HbA1c and HbA1c variability were calculated as the intra-individual mean (HbA1c-MEAN) and standard deviation (HbA1c-SD), respectively, of 4.52±0.76 values. Prevalent CVD, total and by vascular bed, was assessed from medical history by recording previous documented major acute events. Diabetic retinopathy (DR) was assessed by dilated fundoscopy. CKD was defined based on albuminuria, as measured by immunonephelometry or immunoturbidimetry, and estimated glomerular filtration rate, as calculated from serum creatinine. Results: HbA1c-MEAN, but not HbA1c-SD, was significantly higher (P1c-MEAN, and 0.47 (0.29-0.75) and 0.46 (0.28-0.73), respectively, for HbA1c-SD. Logistic regression analyses showed that HbA1c-MEAN, but not HbA1c-SD (and independent of it), was a significant correlate of any CVD. Similar findings were observed in subjects with versus those without any coronary or cerebrovascular event or myocardial infarction. Conversely, none of these measures were associated with stroke, whereas both correlated with any lower limb vascular event and HbA1c-SD alone with ulceration/gangrene. All these associations were independent of known CVD risk factors and microvascular complications (DR and CKD). Conclusions: In patients with type 2 diabetes, HbA1c variability has not a major impact on macrovascular complications, at variance with average HbA1c, an opposite finding as compared with microvascular disease, and particularly nephropathy. Trial registration: ClinicalTrials.Gov NCT00715481
- 5 July 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 1-98
Open AccessHemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study
Background: Previous reports have clearly indicated a significant relationship between hemoglobin (Hb) A1c change from one visit to the next and microvascular complications, especially nephropathy (albuminuria and albuminuric chronic kidney disease, CKD). In contrast, data on macrovascular disease are less clear. This study was aimed at examining the association of HbA1c variability with cardiovascular disease (CVD) in the large cohort of subjects with type 2 diabetes from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Methods: Serial (3–5) HbA1c values obtained during the 2-year period preceding recruitment, including that obtained at the enrolment, were available from 8,290 subjects from 9 centers (out of 15,773 patients from 19 centers). Average HbA1c and HbA1c variability were calculated as the intra-individual mean (HbA1c-MEAN) and standard deviation (HbA1c-SD), respectively, of 4.52±0.76 values. Prevalent CVD, total and by vascular bed, was assessed from medical history by recording previous documented major acute events. Diabetic retinopathy (DR) was assessed by dilated fundoscopy. CKD was defined based on albuminuria, as measured by immunonephelometry or immunoturbidimetry, and estimated glomerular filtration rate, as calculated from serum creatinine. Results: HbA1c-MEAN, but not HbA1c-SD, was significantly higher (P1c-MEAN, and 0.47 (0.29-0.75) and 0.46 (0.28-0.73), respectively, for HbA1c-SD. Logistic regression analyses showed that HbA1c-MEAN, but not HbA1c-SD (and independent of it), was a significant correlate of any CVD. Similar findings were observed in subjects with versus those without any coronary or cerebrovascular event or myocardial infarction. Conversely, none of these measures were associated with stroke, whereas both correlated with any lower limb vascular event and HbA1c-SD alone with ulceration/gangrene. All these associations were independent of known CVD risk factors and microvascular complications (DR and CKD). Conclusions: In patients with type 2 diabetes, HbA1c variability has not a major impact on macrovascular complications, at variance with average HbA1c, an opposite finding as compared with microvascular disease, and particularly nephropathy. Trial registration: ClinicalTrials.Gov NCT00715481
- Open Access
- 1 May 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (suppl 1) , i299-i308
Cell signalling
Introduction and Aims: Klotho is a protein that has anti-aging properties and is known to function as an obligate co-receptor of FGF23 in the regulation of phosphate homeostasis and also to be involved in insulin/IGF1 and WNT signaling, suggesting that Klotho has several biological properties in physiological and pathophysiological conditions. It has been reported that the renal expression of the Klotho gene is markedly suppressed in chronic kidney disease (CKD). Acceleration of renal fibrosis is a basic pathophysiology for progression of CKD, and previously, we showed that the renal interstitial fibrosis was severer in the kl +/- mice than those in the wild-type mice by UUO treatment. Thus, in the present study we investigated the biological role of Klotho in the process of fibrosis in cultured cells.
- 1 May 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (suppl 1) , i299-i308
Open AccessCell signalling
Introduction and Aims: Klotho is a protein that has anti-aging properties and is known to function as an obligate co-receptor of FGF23 in the regulation of phosphate homeostasis and also to be involved in insulin/IGF1 and WNT signaling, suggesting that Klotho has several biological properties in physiological and pathophysiological conditions. It has been reported that the renal expression of the Klotho gene is markedly suppressed in chronic kidney disease (CKD). Acceleration of renal fibrosis is a basic pathophysiology for progression of CKD, and previously, we showed that the renal interstitial fibrosis was severer in the kl +/- mice than those in the wild-type mice by UUO treatment. Thus, in the present study we investigated the biological role of Klotho in the process of fibrosis in cultured cells.
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 719
Relationship between full islet transplanted function and secondary diabetic complications: a case report
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 719
Relationship between full islet transplanted function and secondary diabetic complications: a case report
- Open Access
- 11 April 2012
- Published by Hindawi Limited in Experimental Diabetes Research
- Vol. 2012, 1-8
The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
Although cellular and molecular bases of proliferative diabetic retinopathy are only partially understood, it is evident that this complication of diabetes is characterized by the formation of new vessels inside the retina showing abnormal architecture and permeability. This process, if not controlled by selective laser photocoagulation, leads to irreversible retinal damages and loss of vision. Angiogenesis, that is, the condition characterized by the growth of new blood vessels originated from preexisting ones, was shown to have a major role in the pathogenesis of proliferative retinopathy and, as a consequence, intravitreal antiangiogenic injection was suggested as a feasible treatment for this disease. Here, we describe the different antiangiogenic approaches used to treat this disease along with the respective advantages and limitations when compared to laser treatment. Altogether, even though further and longer studies are still needed to clarify the best possible therapeutic protocol, the antiangiogenic treatment will reasonably have a future role in the therapy and prevention of proliferative diabetic retinopathy.
- 11 April 2012
- Published by Hindawi Limited in Experimental Diabetes Research
- Vol. 2012, 1-8
Open AccessThe Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
Although cellular and molecular bases of proliferative diabetic retinopathy are only partially understood, it is evident that this complication of diabetes is characterized by the formation of new vessels inside the retina showing abnormal architecture and permeability. This process, if not controlled by selective laser photocoagulation, leads to irreversible retinal damages and loss of vision. Angiogenesis, that is, the condition characterized by the growth of new blood vessels originated from preexisting ones, was shown to have a major role in the pathogenesis of proliferative retinopathy and, as a consequence, intravitreal antiangiogenic injection was suggested as a feasible treatment for this disease. Here, we describe the different antiangiogenic approaches used to treat this disease along with the respective advantages and limitations when compared to laser treatment. Altogether, even though further and longer studies are still needed to clarify the best possible therapeutic protocol, the antiangiogenic treatment will reasonably have a future role in the therapy and prevention of proliferative diabetic retinopathy.
- Open Access
- 14 March 2012
- Published by American Diabetes Association in Diabetes
- Vol. 61 (4) , 908-914
Endothelial Progenitor Cells Carrying Monocyte Markers Are Selectively Abnormal in Type 1 Diabetic Patients With Early Retinopathy
Endothelial progenitor cells (EPCs) enter the systemic circulation in response to cues related to vascular damage and need for neovascularization. Thus, EPCs could become readily accessible informers of vascular status and enable the survey of vascular pathologies during preclinical stages. To identify EPC changes with biomarker potential, we investigated whether discrete EPC abnormalities were associated with early nonproliferative diabetic retinopathy (NPDR). Two EPC subtypes with different functions have been characterized to date—one solely committed to the endothelial lineage and the other carrying both endothelial and monocytic markers. We found that only the latter, colony-forming units (CFU)-Hill cells, manifested abnormalities in type 1 diabetic patients with NPDR compared with control subjects. The abnormalities consisted in an increased number of colonies formed in vitro and downregulation of the molecules that facilitate homing at sites of vascular injury. The abnormalities were absent in type 1 diabetic patients free of retinopathy and other complications, despite long diabetes duration, but were detected in some of the patients without clinical retinopathy after short diabetes duration. CFU-Hill cells are potential informers of diabetic microangiopathy but may be preempted from carrying out reparative functions if the molecular abnormalities compromise interactions with the damaged vascular wall.
- 14 March 2012
- Published by American Diabetes Association in Diabetes
- Vol. 61 (4) , 908-914
Open AccessEndothelial Progenitor Cells Carrying Monocyte Markers Are Selectively Abnormal in Type 1 Diabetic Patients With Early Retinopathy
Endothelial progenitor cells (EPCs) enter the systemic circulation in response to cues related to vascular damage and need for neovascularization. Thus, EPCs could become readily accessible informers of vascular status and enable the survey of vascular pathologies during preclinical stages. To identify EPC changes with biomarker potential, we investigated whether discrete EPC abnormalities were associated with early nonproliferative diabetic retinopathy (NPDR). Two EPC subtypes with different functions have been characterized to date—one solely committed to the endothelial lineage and the other carrying both endothelial and monocytic markers. We found that only the latter, colony-forming units (CFU)-Hill cells, manifested abnormalities in type 1 diabetic patients with NPDR compared with control subjects. The abnormalities consisted in an increased number of colonies formed in vitro and downregulation of the molecules that facilitate homing at sites of vascular injury. The abnormalities were absent in type 1 diabetic patients free of retinopathy and other complications, despite long diabetes duration, but were detected in some of the patients without clinical retinopathy after short diabetes duration. CFU-Hill cells are potential informers of diabetic microangiopathy but may be preempted from carrying out reparative functions if the molecular abnormalities compromise interactions with the damaged vascular wall.
- 1 January 2012
- Published by Springer Nature
- p. 17-21
The Cell Membrane of the Contractile Unit